Alendronate inhibits urinary calcium microlith formation in a three-dimensional culture model

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Urological research

• Publication date

  2004-04-03

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1007/s00240-004-0409-7PMID 15064876
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Morphological analysis of renal cell culture models of calcium phosphate stone formation

  2004influential reference
• Expression of osteopontin in rat kidneys: induction during ethylene glycol induced calcium oxalate nephrolithiasis.

  2002cited by this paper
• Calcium phosphate stones produced by Madin-Darby canine kidney(MDCK)cells inoculated in nude mice

  2000cited by this paper
• Calcium phosphate stones produced by Madin-Darby canine kidney (MDCK) cells inoculated in nude mice

  1999cited by this paper
• Alendronate decreases urine calcium and supersaturation in genetic hypercalciuric rats.

  1999cited by this paper
• Comparison of Cytotoxic Effects of Bisphosphonates In Vitro and In Vivo

  1998cited by this paper
• Alendronate inhibits osteopontin expression enhanced by parathyroid hormone-related peptide (PTHrP) in the rat kidney

  1998cited by this paper
• Effects of Etidronate Disodium on Crystallizations in Synthetic Urine and Calcium Oxalate Crystal Adhesion to Madin‐Darby Canine Kidney (MDCK) Cells

  1998cited by this paper
• Microlith Formation In Vitro by Madin Darby Canine Kidney (MDCK) Cells

  1996cited by this paper
• Effect of Oral Alendronate on Bone Mineral Density and the Incidence of Fractures in Postmenopausal Osteoporosis

  1996cited by this paper
• Beta-glycerophosphate accelerates calcification in cultured bovine vascular smooth muscle cells.

  1995cited by this paper
• β-Glycerophosphate Accelerates Calcification in Cultured Bovine Vascular Smooth Muscle Cells

  1995cited by this paper
• Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.

  1995cited by this paper
• Prevention of hypercalciuria and stone‐forming propensity during prolonged bedrest by alendronate

  1995cited by this paper
• Alendronate distributed on bone surfaces inhibits osteoclastic bone resorption in vitro and in experimental hypercalcemia models.

  1995cited by this paper
• Structure and expression of the mRNA encoding urinary stone protein (osteopontin).

  1993cited by this paper
• Molecular cloning and sequencing of cDNA encoding urinary stone protein, which is identical to osteopontin.

  1992cited by this paper
• Bisphosphonates

  1991cited by this paper
• Etiology and treatment of urolithiasis.

  1991cited by this paper
• Madin-Darby canine kidney cells

  1990cited by this paper
• Madin-Darby canine kidney cells

  1990cited by this paper
• The first kidney stone.

  1989cited by this paper
• Developmental expression of 2ar (osteopontin) and SPARC (osteonectin) RNA as revealed by in situ hybridization

  1988cited by this paper
• Bisphosphonates--history and experimental basis.

  1987cited by this paper
• Cloning and sequence analysis of rat bone sialoprotein (osteopontin) cDNA reveals an Arg-Gly-Asp cell-binding sequence.

  1986cited by this paper
• Treatment of calcium urolithiasis with diphosphonate: efficacy and hazards.

  1979cited by this paper
• The effect of ethane-1-hydroxy-1,1-diphosphonate (EHDP) on calcium oxalate crystalluria in recurrent renal stoneformers.

  1974cited by this paper
• THE EFFECT OF E THANE-1-HYDR OXY-1,l- DIPHOSPHONATE (EHDP) ON CALCIUM OXALATE FORMERS CRYSTALLURIA IN RECURRENT RENAL STONE-

  1974cited by this paper
• Organic matrix of human urinary concretions.

  1968cited by this paper
• Characterization of an Established Line of Canine Kidney Cells (MDCK).∗ †

  1966cited by this paper

• Drug-induced kidney stones: a real-world pharmacovigilance study using the FDA adverse event reporting system database

  2025cites this paper
• Characterization of a Unique Spontaneous Calcifying Cell Line (CJ): a Novel Tool for the Study of Ectopic Calcification

  2024cites this paper
• Urinary calculi in larvae of striped trumpeter, Latris lineata.

  2022cites this paper
• Effect of bisphosphonates on the crystallization of stone-forming salts in synthetic urine

  2020cites this paper
• Bisphosphonates and management of kidney stones and bone disease

  2020cites this paper
• Urolithiasis increases the risk of subsequent onset of osteoporosis

  2019cites this paper
• Pharmacology Risk Report

  2018cites this paper
• Understanding the Pathophysiology of Nephrocalcinosis

  2017cites this paper
• Low Bone Density and Bisphosphonate Use and the Risk of Kidney Stones.

  2017cites this paper
• How do stones form? Is unification of theories on stone formation possible?

  2017cites this paper
• Urolithiasis is associated with the increased risk for osteoporosis: A nationwide 9-year follow-up study

  2017cites this paper
• Role of Osteogenesis in the Formation of Randall's Plaques

  2016cites this paper
• Treatment with hydrochlorothiazide and alendronate in patients with stones and bone mineral density loss. Evolution of bone metabolism and calciuria with medical treatment.

  2016cites this paper
• Urine Calcium and Bone Mineral Density in Calcium Stone-Forming Patients Treated with Alendronate and Hydrochlorothiazide

  2016cites this paper
• Inhibitory actions by ibandronate sodium, a nitrogen-containing bisphosphonate, on calcium-activated potassium channels in Madin–Darby canine kidney cells

  2015cites this paper
• Reactive oxygen species, inflammation and calcium oxalate nephrolithiasis

  2014cites this paper
• Unified theory on the pathogenesis of Randall’s plaques and plugs

  2014cites this paper
• Re: effects of aminobisphosphonates and thiazides in patients with osteopenia/osteoporosis, hypercalciuria, and recurring renal calcium lithiasis.

  2013cites this paper
• Association between osteoporosis and urinary calculus: evidence from a population-based study

  2013cites this paper
• Calcium supplementation and kidney stone risk in osteoporosis: a systematic literature review.

  2012cites this paper
• Biomolecular mechanism of urinary stone formation involving osteopontin

  2012cites this paper
• Effects of aminobisphosphonates and thiazides in patients with osteopenia/osteoporosis, hypercalciuria, and recurring renal calcium lithiasis.

  2012cites this paper
• Medicinal surface modification of silicon nanowires: impact on calcification and stromal cell proliferation.

  2009cites this paper
• Effects of sodium alendronate on body weight and water and food intake of adult female Wistar rats

  2009cites this paper
• Urolithiasis and osteoporosis: clinical relevance and therapeutic implications.

  2009cites this paper
• Alendronate Reduces the Excretion of Risk Factors for Calcium Phosphate Stone Formation in Postmenopausal Women with Osteoporosis

  2009cites this paper
• CHAPTER 50 – Diseases of the Urinary Bladder

  2008cites this paper
• Are New-Generation Bisphosphonates Effective for the Inhibition of Calcium Oxalate Stone Formation in a Rat Model?

  2008cites this paper
• Factors affecting the regrowth of renal stones in vitro: A contribution to the understanding of renal stone development

  2005cites this paper